AbbVie Inc (ABBV) : Wealth Architects reduced its stake in AbbVie Inc by 8.68% during the most recent quarter end. The investment management company now holds a total of 5,386 shares of AbbVie Inc which is valued at $360,593 after selling 512 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.AbbVie Inc makes up approximately 0.17% of Wealth Architects’s portfolio.
Other Hedge Funds, Including , Saturna Capital Corp reduced its stake in ABBV by selling 394 shares or 0.1% in the most recent quarter. The Hedge Fund company now holds 383,561 shares of ABBV which is valued at $25,679,409. AbbVie Inc makes up approx 0.79% of Saturna Capital Corp’s portfolio.Kornitzer Capital Management Inc Ks reduced its stake in ABBV by selling 850 shares or 1.22% in the most recent quarter. The Hedge Fund company now holds 68,698 shares of ABBV which is valued at $4,549,869. AbbVie Inc makes up approx 0.08% of Kornitzer Capital Management Inc Ks’s portfolio.Grandfield Dodd reduced its stake in ABBV by selling 314 shares or 2.54% in the most recent quarter. The Hedge Fund company now holds 12,032 shares of ABBV which is valued at $796,879. AbbVie Inc makes up approx 0.11% of Grandfield Dodd’s portfolio.High Point Bank Trust Co reduced its stake in ABBV by selling 200 shares or 0.53% in the most recent quarter. The Hedge Fund company now holds 37,186 shares of ABBV which is valued at $2,413,371. AbbVie Inc makes up approx 0.66% of High Point Bank Trust Co’s portfolio.Capital Planning Advisors reduced its stake in ABBV by selling 465 shares or 2.36% in the most recent quarter. The Hedge Fund company now holds 19,279 shares of ABBV which is valued at $1,230,193. AbbVie Inc makes up approx 0.66% of Capital Planning Advisors’s portfolio.
AbbVie Inc opened for trading at $67.47 and hit $68.1239 on the upside on Monday, eventually ending the session at $67.39, with a gain of 0.30% or 0.2 points. The heightened volatility saw the trading volume jump to 52,15,360 shares. Company has a market cap of $109,747 M.
On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.